Author

R. M. Evans

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1 Cancer Biology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:mouse· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:metabolomics· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

M. Downes· 5 shared A. R. Atkins· 2 shared C. Liddle· 2 shared R. T. Yu· 2 shared A. Denardo· 1 shared A. E. Clark· 1 shared A. F. Garretson· 1 shared A. F. M. Pinto· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

M. Downes

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression

G. Liang, T. G. Oh, N. Hah, H. Tiriac, Y. Shi, M. L. Truitt, C. E. Antal, A. R. Atkins, Y. Li, C. Fraser, S. Ng, A. F. Pinto, D. C. Nelson, S. Bashi, E. Banayo, , R. M. Evans

This study shows that inhibiting stromal Class I HDACs reduces pancreatic cancer progression by targeting desmoplastic and pro-tumorigenic programs in cancer-associated fibroblasts.

Nature Communications · Dec 6, 2023Peer-reviewedCancer Biology

Novel ERR pan-agonists ameliorate heart failure through boosting cardiac fatty acid metabolism and mitochondrial function

W. Xu, C. Billon, H. Li, M. Hayes, K. Yu, M. Losby, C. S. Hampton, C. M. Adeyemi, A. Graves, E. Nasiotis, C. Fu, R. Welch, R. M. Evans, L. Pei, J. K. Walker, , L. Zhang

This study develops two ERR agonists that improve heart failure by enhancing fatty acid metabolism and mitochondrial function in mice.

bioRxiv · Feb 14, 2022 · PreprintPharmacology & Toxicology

Bisphenol A derivatives act as novel coactivator binding inhibitors for estrogen receptor β

M. Iwamoto, T. Masuya, M. Hosose, K. Tagawa, T. Ishibashi, E. Yoshihara, M. Downes, R. M. Evans, A. Matsushima

This study identifies bisphenol A derivatives as novel coactivator binding inhibitors for estrogen receptor β, showing dual agonist/antagonist activities and a new ligand interaction site.

bioRxiv · May 10, 2021Biochemistry

The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection

D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch

This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.

bioRxiv · Mar 22, 2021 · PreprintMicrobiology

Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses

S. Xu, O. Chaudhary, P. Rodriguez-Morales, X. Sun, R. Zappasodi, Z. Xu, A. F. M. Pinto, A. Williams, D. Chen, J. S. Low, Y. Farsakoglu, W. Tang, H. Wang, S. K. Varanasi, B. McDonald, , S. M. Kaech

This study identifies CD36-mediated lipid peroxidation driven by oxidized lipids as a mechanism suppressing anti-tumor CD8 T cell functions in murine tumors.

bioRxiv · Sep 3, 2020Immunology

Obesity Potentiates TH2 Immunopathology via Dysregulation of PPAR

S. Bapat, Y. Liang, S. Liu, L.-j. Zhang, I. Vogel, D. J. Marr, C. Zhou, E. J. Choi, C. Chang, N. He, M. LeBlanc, I.-k. Lee, J. M. Suh, L. E. Crotty Alexander, C. Liddle, , Y. Zheng

This study shows obesity increases TH2 immunopathology by disrupting PPARγ in T cells, and TZDs can protect against this effect in obese mice.

bioRxiv · Oct 31, 2019 · PreprintImmunology